These analyses suggest that initiating therapy with DRSP/EE may be a cost-effective option in the treatment of PMDD. </AbstractSection> Copyright Adis Data Information BV 2010

Background: Premenstrual syndrome (PMS) is reported to affect between 13% and 31% of women. Between 3% and 8% of women are reported to meet criteria for the more severe form of PMS, premenstrual dysphoric disorder (PMDD). Although PMDD has received increased attention in recent years, the cost...